Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase I clinical trial for the treatment of phenylketonuria; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in Phase III clinical trial for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTRX
Previous Symbol
CUSIPN/A
Phone760-260-8600
Debt
Debt-to-Equity Ratio0.60
Current Ratio5.04
Quick Ratio4.99
Price-To-Earnings
Trailing P/E Ratio-16.21
Forward P/E Ratio-9.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$154.94 million
Price / Sales6.47
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.46 per share
Price / Book3.26
Profitability
EPS (Most Recent Fiscal Year)($1.50)
Net Income$-59,730,000.00
Net Margins-69.38%
Return on Equity-35.43%
Return on Assets-19.07%
Miscellaneous
Employees173
Outstanding Shares41,250,000
Market Cap$990.77 million
OptionableOptionable
Retrophin (NASDAQ:RTRX) Frequently Asked Questions
What is Retrophin's stock symbol?
Retrophin trades on the NASDAQ under the ticker symbol "RTRX."
How were Retrophin's earnings last quarter?
Retrophin Inc (NASDAQ:RTRX) announced its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.39. The biopharmaceutical company had revenue of $40.70 million for the quarter, compared to analysts' expectations of $44.36 million. Retrophin had a negative return on equity of 35.43% and a negative net margin of 69.38%. The firm's revenue for the quarter was up 1.0% on a year-over-year basis. During the same period last year, the company posted $0.15 earnings per share. View Retrophin's Earnings History.
When is Retrophin's next earnings date?
What price target have analysts set for RTRX?
4 brokers have issued 1 year price targets for Retrophin's shares. Their predictions range from $43.00 to $57.00. On average, they expect Retrophin's stock price to reach $48.00 in the next year. This suggests a possible upside of 97.4% from the stock's current price. View Analyst Price Targets for Retrophin.
What is the consensus analysts' recommendation for Retrophin?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.
Has Retrophin been receiving favorable news coverage?
News coverage about RTRX stock has trended positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Retrophin earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Who are some of Retrophin's key competitors?
Some companies that are related to Retrophin include GW Pharmaceuticals PLC- (GWPH), Emergent Biosolutions (EBS), Horizon Pharma (HZNP), Array Biopharma (ARRY), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Agios Pharmaceuticals (AGIO), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Allakos (ALLK), Endo International (ENDP), Blueprint Medicines (BPMC) and Ultragenyx Pharmaceutical (RARE).
Who are Retrophin's key executives?
Retrophin's management team includes the folowing people:
- Mr. Stephen J. Aselage, CEO, Pres & Director (Age 67)
- Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 59)
- Mr. Neil F. McFarlane, Chief Operating Officer (Age 45)
- Ms. Elizabeth E. Reed, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47)
- Dr. William E. Rote, Sr. VP of R&D (Age 55)
Who are Retrophin's major shareholders?
Retrophin's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.68%), Macquarie Group Ltd. (4.67%), The Manufacturers Life Insurance Company (4.47%), Dimensional Fund Advisors LP (2.64%), Jennison Associates LLC (1.93%) and TIAA CREF Investment Management LLC (1.41%). Company insiders that own Retrophin stock include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.
Which institutional investors are selling Retrophin stock?
RTRX stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, TIAA CREF Investment Management LLC, Lombard Odier Asset Management USA Corp, JPMorgan Chase & Co., Prudential Financial Inc., Oak Ridge Investments LLC, Sphera Funds Management LTD. and Fisher Asset Management LLC. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin.
Which institutional investors are buying Retrophin stock?
RTRX stock was acquired by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Macquarie Group Ltd., Dimensional Fund Advisors LP, Handelsbanken Fonder AB, First Trust Advisors LP, Jane Street Group LLC, PNC Financial Services Group Inc. and Panagora Asset Management Inc.. View Insider Buying and Selling for Retrophin.
How do I buy shares of Retrophin?
Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Retrophin's stock price today?
One share of RTRX stock can currently be purchased for approximately $24.31.
How big of a company is Retrophin?
Retrophin has a market capitalization of $990.77 million and generates $154.94 million in revenue each year. The biopharmaceutical company earns $-59,730,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Retrophin employs 173 workers across the globe.
What is Retrophin's official website?
How can I contact Retrophin?
Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]
MarketBeat Community Rating for Retrophin (NASDAQ RTRX)
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
